A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- Drug: MRG003 + PucotenlimabDrug: Gemcitabine, Docetaxel, or Capecitabine
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT06976190
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
- Conditions
- Advanced or Metastatic Urothelium Cancer
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05754853
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05751512
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: MRG003+HX008
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05688605
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- Drug: MRG002+HX008
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05338957
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT05263869
- Locations
- 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
- Conditions
- Advanced or Metastatic Gastroesophageal Junction CarcinomaAdvanced or Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05188209
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Henan Tumor Hospital, Zhengzhou, Henan, China
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT05155839
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University Cancer Hospital & Institute, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction CancerLocally Advanced Gastric Cancer
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05141747
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanghai Oriental Hospital, Shanghai, Shanghai, China
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05141786
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China